^
Association details:
| Biomarker: | TMB-H |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | sasanlimab (PF-06801591) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma
Published date:
06/27/2023
Excerpt:
Sixty-eight and 38 patients with NSCLC and urothelial carcinoma, respectively, received subcutaneous sasanlimab....The response rate was higher in patients with high PD-L1 expression [ORR (95% CI) 36.4% (10.9% to 69.2%) in PD-L1 ≥50% versus 14.3% (4.0% to 32.7%) in PD-L1 <1%] and high TMB (ORR 41.7% in high TMB versus 8.3% in low TMB) (Table 3; Figure 1)….Subcutaneous sasanlimab at 300 mg q4w was well tolerated with promising clinical efficacy observed.
DOI:
10.1016/j.esmoop.2023.101589
Trial ID:
